These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24845012)

  • 1. [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
    John A; Michel MS
    Urologe A; 2014 Jun; 53(6):893-902; quiz 903. PubMed ID: 24845012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative management of patients on new oral anticoagulants.
    Lai A; Davidson N; Galloway SW; Thachil J
    Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
    Blann AD
    Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
    Kornej J; Potpara T; Lip GY
    Pol Arch Med Wewn; 2013; 123(11):623-34. PubMed ID: 24104195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
    Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants in atrial fibrillation.
    Noll G; Noll S; Hürlimann D
    Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
    Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
    Lazo-Langner A; Lang ES; Douketis J
    Crit Care; 2013 Jun; 17(3):230. PubMed ID: 23806169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH
    Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The laboratory and the new oral anticoagulants.
    Tripodi A
    Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.